Inhibition of multidrug resistance-associated protein (MRP) activity by rifampicin in human multidrug-resistant lung tumor cells

Cancer Letters

Volumn 139, Issue 1, 1999, Pages 97-104

  Courtois, Arnaud ^a   Payen, Léa ^a   Vernhet, Laurent ^a   De Vries, Elisabeth G E ^b   Guillouzo, André ^a   Fardel, Olivier ^a  

^a INSERM   (France)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anticancer drugs; Calcein; Chemosensitizer; Multidrug resistance associated protein (MRP); Rifampicin

Indexed keywords

CALCEIN; DOXORUBICIN; GUANINE NUCLEOTIDE BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN; RIFAMPICIN; RIFAMYCIN; RIFAMYCIN B; TUBERCULOSTATIC AGENT; VINCRISTINE;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG SENSITIVITY; DRUG TRANSPORT; HUMAN; HUMAN CELL; LUNG CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTITUBERCULAR; ATP-BINDING CASSETTE TRANSPORTERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; FLUORESCEINS; HUMANS; LUNG NEOPLASMS; MODELS, CHEMICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RIFAMPIN; RIFAMYCINS; TUMOR CELLS, CULTURED;

EID: 0032899930     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00024-5     Document Type: Article

References (33)

1. Hayes J.D., Wolf R. Molecular mechanism of drug resistance. Biochem. J. 272:1990;281-295.
2. Bellamy W.T., Dalton W.S. Multidrug resistance in the laboratory and clinic. Adv. Clin. Chem. 31:1994;1-61.
3. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
4. Van den Bliek A.M., Borst P. Multidrug resistance. Adv. Cancer Res. 52:1989;165-263.
5. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M.V., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1654.
6. Lautier D., Canitrot Y., Deeley R.G., Cole S.P.C. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem. Pharmacol. 52:1996;967-977.
7. Cole S.P.C., Sparks K.E., Fraser K., Loe D.W., Grant C.E., Wilson G.M., Deeley R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54:1994;5902-5910.
8. Nooter K., Herweijer H. Multidrug resistance (mdr) in human cancer. Br. J. Cancer. 63:1991;663-669.
9. Burger H., Nooter K., Sonneveld P., van Wingerden K.E., Zaman G.J.R., Stoter G. High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukemia. Br. J. Haematol. 88:1994;348-356.
10. Wright S.R., Boag A.H., Valdimarsson G., Hipfner D.R., Campling B.G., Cole S.P.C., Deeley R.G. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin. Cancer Res. 4:1998;2279-2289.
11. Goasguen J.E., Dossot J.M., Fardel O., Le Mée F., Le Gall E., Le Prisé P.Y., Chaperon J., Fauchet R. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood. 81:1993;2394-2398.
12. Ford J.M., Hait W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 8:1990;137-171.
13. Sikic B.I. Modulation of multidrug resistance: at the threshold. J. Clin. Oncol. 11:1993;1629-1635.
14. Miller R.L., Bukowski R.M., Budd G.T., Midha K.K., Ganapathi R. Clinical modulation of doxorubicin resistance by the calmodulin inhibitor trifluoperazine: a phase I/II trial. J. Clin. Oncol. 6:1988;880-888.
15. Barrand M.A., Rhodes T., Center M.S., Twentyman P.R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur. J. Cancer. 29A:1993;408-415.
16. Wehrli W. Ansamycins - chemistry, biosynthesis and biological activity. Top. Curr. Chem. 72:1977;21-49.
17. Fardel O., Lecureur V., Loyer P., Guillouzo A. Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem. Pharmacol. 49:1995;1255-1260.
18. Furusawa S., Nakano S., Wu J., Sasaki K., Takayanagi M., Takayanagi Y. Potentiation of pirarubicin activity in multidrug resistant cells by rifampicin. Biol. Pharm. Bull. 20:1997;1303-1306.
19. Zaman G.J.R., Vertsantvoort C.H.M., Smit J.J.M., Eijdems E.W.H.M., de Haas M., Smith A.J., Broxterman H.J., Mulder N.H., de Vries E.G.E., Baas F., Borst P. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 53:1993;1747-1750.
20. Feller N., Broxterman H.J., Währer D.C.R., Pinedo H.M. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett. 368:1995;385-388.
21. Haugland R.P. Probes for live-cell function. Spence M.T.Z. Handbook of Fluorescent Probes and Research Chemicals. 1996;377-398 Molecular Probes, Eugene.
22. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
23. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:1987;936-942.
24. Ford J.M., Prozialek W.C., Hait W.N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 35:1989;105-115.
25. Versantvoort C.H.M., Bagru T., Wright K.A., Twentyman P.R. On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP). Int. J. Cancer. 63:1995;855-862.
26. Manzano R.G., Wright K.A., Twentyman P.R. Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP). Clin. Cancer Res. 2:1996;1321-1326.
27. Leier I., Jedlitschky G., Buchholz U., Cole S.P.C., Deeley R.G., Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 269:1994;27807-27810.
28. Hirai M., Tanaka K., Shimizu T., Tanigawara Y., Yasuhara M., Hori R., Kakehi Y., Yoshida O., Ueda K., Komano T., Inui K.I. Cepharantin, a multidrug resistant modifier, is a substrate for P-glycoprotein. J. Pharmacol. Exp. Ther. 275:1995;73-78.
29. Acocella G. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 3:1978;586-592.
30. Versantvoort C.H.M., Schuurhuis G.J., Pinedo H.M., Eekman C.A., Kuiper C.M., Lankelma J., Broxterman H.J. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br. J. Cancer. 68:1993;939-946.
31. Rhodes T., Barrand M.A., Twentyman P.R. Modification by brefeldin A, bafilomycin A1 and 7-chloro-4-nitobenz-2-oxa-1,3-diazole (NBD) of cellular accumulation and intracellular distribution of anthracyclins in the non-P-glycoprotein-mediated multidrug-resistant cell lines COR-L23/R. Br. J. Cancer. 70:1994;60-66.
32. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49:1996;311-318.
33. Calleja C., Pascussi J.M., Mani J.C., Maurel P., Vilarem M.J. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucorticoid receptor. Nat. Med. 4:1998;92-96.